MedTrace Logo

PD1-CD19-CART in Patients With r/r B-cell Lymphoma

NCT04213469 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-01-05

No results posted yet for this study

Summary

This is an open label, single-site, dose-escalation study in up to 25 participants with relapse/refractory B-NHL. This study aims to evaluate the safety and efficacy of the treatment with PD1-CD19-CART.

Conditions

Interventions

BIOLOGICAL

PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells

Gene editing autologous T cells with anti-CD19 ScFv expression and knockout of PD1

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • Bioray Laboratories

    lead INDUSTRY

Principal Investigators

  • He Huang, Prof · the First Affliated Hospital, Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-13
Primary Completion
2021-11-01
Completion
2023-11-10

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04213469 on ClinicalTrials.gov